MicroRNA involvement in gastrointestinal stromal tumor tumorigenesis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current pharmaceutical design

• Publication date

  2012-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161213804805748PMID 23092343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developing microRNA therapeutics.

  2012cited by this paper
• Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

  2012cited by this paper
• MicroRNAs in vascular and metabolic disease.

  2012cited by this paper
• Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer.

  2011cited by this paper
• Bio-inspired, bioengineered and biomimetic drug delivery carriers

  2011cited by this paper
• Nanoparticle carriers based on copolymers of poly(ε-caprolactone) and hyperbranched polymers for drug delivery.

  2011cited by this paper
• MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation

  2011cited by this paper
• Five years of siRNA delivery: spotlight on gold nanoparticles.

  2011cited by this paper
• MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy

  2011cited by this paper
• MicroRNAs in the pathogenesis of cancer.

  2011cited by this paper
• SiRNA delivery: challenges and role of carrier systems.

  2011cited by this paper
• Crystal structure of a novel type of odorant-binding protein from Anopheles gambiae, belonging to the C-plus class.

  2011cited by this paper
• Non-coding RNAs in human disease

  2011cited by this paper
• MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia

  2011cited by this paper
• Heterozygosity Loss at 22q and Lack of INI1 Gene Mutation in Gastrointestinal Stromal Tumor

  2011cited by this paper
• Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors

  2011cited by this paper
• MicroRNAs in body fluids—the mix of hormones and biomarkers

  2011cited by this paper
• MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation

  2011cited by this paper
• Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients.

  2011cited by this paper
• Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

  2011cited by this paper
• Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis

  2011cited by this paper
• BRAF mutation status in gastrointestinal stromal tumors.

  2010cited by this paper
• Gastrointestinal stromal tumors

  2010cited by this paper
• Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.

  2010cited by this paper
• MicroRNAs: novel biomarkers for gastrointestinal carcinomas

  2010cited by this paper
• MicroRNA expression profile of gastrointestinal stromal tumors is distinguished by 14q loss and anatomic site

  2010cited by this paper
• Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

  2010cited by this paper
• A targeted approach to miRNA target identification

  2010cited by this paper
• Rational design of cationic lipids for siRNA delivery

  2010cited by this paper
• A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number

  2010cited by this paper
• Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis

  2010cited by this paper
• Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.

  2010cited by this paper
• Localization‐ and mutation‐dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co‐expressed miRNAs located at 14q32.31

  2010cited by this paper
• V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours

  2009cited by this paper
• Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas

  2009cited by this paper
• Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

  2009cited by this paper
• KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

  2009cited by this paper
• Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression

  2009cited by this paper
• MicroRNA profiling of human gastric cancer.

  2009cited by this paper
• MicroRNA-dependent regulation of cKit in cutaneous melanoma.

  2009cited by this paper
• Pathological characteristics of gastrointestinal stromal tumours with PDGFRA mutations

  2009cited by this paper
• Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.

  2009cited by this paper
• Novel functions for small RNA molecules.

  2009cited by this paper
• Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

  2008cited by this paper
• Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors

  2008cited by this paper
• Applying small RNA molecules to the directed treatment of human diseases: realizing the potential

  2008cited by this paper
• Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)

  2008cited by this paper
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

  2008cited by this paper
• Heterogeneity of kinase inhibitor resistance mechanisms in GIST

  2008cited by this paper
• Exploration of Small RNAs

  2008cited by this paper
• Distinct gene expression-defined classes of gastrointestinal stromal tumor.

  2008cited by this paper
• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

  2008cited by this paper
• Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

  2008cited by this paper
• Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

  2008cited by this paper
• MicroRNA expression signature of human sarcomas

  2008cited by this paper
• Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

  2008cited by this paper
• MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death

  2008cited by this paper
• Overcoming the Innate Immune Response to Small Interfering RNA

  2008cited by this paper
• microRNA functions.

  2007cited by this paper
• Secondary c-kit Mutation in a Recurrent Gastrointestinal Stromal Tumor Under Long-Term Treatment with Imatinib Mesylate: Report of a Case

  2007cited by this paper
• Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS.

  2007cited by this paper
• KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

  2007cited by this paper
• The guardian's little helper: microRNAs in the p53 tumor suppressor network.

  2007cited by this paper
• Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

  2007cited by this paper
• An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications

  2007cited by this paper
• Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status

  2007cited by this paper
• The role of KIT in the management of patients with gastrointestinal stromal tumors.

  2007cited by this paper
• KIT mutations in GIST.

  2007cited by this paper
• Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors

  2007cited by this paper
• Second line therapies for the treatment of gastrointestinal stromal tumor

  2007cited by this paper
• KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

  2006cited by this paper
• Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

  2006cited by this paper
• Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

  2006cited by this paper
• Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate.

  2006cited by this paper
• Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations

  2006cited by this paper
• Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

  2006cited by this paper
• MicroRNA signatures in human cancers

  2006cited by this paper
• Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas.

  2006cited by this paper
• Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

  2006cited by this paper
• Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

  2006cited by this paper
• The stem cell factor receptor/c-Kit as a drug target in cancer.

  2006cited by this paper
• Vector-based RNAi approaches for stable, inducible and genome-wide screens.

  2006cited by this paper
• Gastrointestinal stromal tumors: pathology and prognosis at different sites.

  2006cited by this paper
• Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases

  2005cited by this paper
• MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

  2005cited by this paper
• Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up

  2005cited by this paper
• Principles of MicroRNA–Target Recognition

  2005cited by this paper
• Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors

  2005cited by this paper
• PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

  2005cited by this paper
• Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

  2005cited by this paper
• KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.

  2005cited by this paper
• Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala

  2005cited by this paper
• Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature

  2005cited by this paper
• Prevalence of KIT expression in human tumors.

  2004cited by this paper
• Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)

  2004cited by this paper
• Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site

  2004cited by this paper
• Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

  2004cited by this paper
• Clustering of molecular alterations in gastroesophageal carcinomas.

  2004cited by this paper

• MicroRNA expression signature in gastrointestinal stromal tumour & their molecular & histological features

  2024cites this paper
• Análisis de marcadores tumorales en pacientes con tumores estromales gastrointestinales GIST

  2023cites this paper
• Role of non-coding RNAs in pathogenesis of gastrointestinal stromal tumors

  2020cites this paper
• MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours

  2018cites this paper
• miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT

  2018cites this paper
• Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.

  2018cites this paper
• Promoter methylation of PCDH10 by HOTAIR regulates the progression of gastrointestinal stromal tumors

  2016cites this paper
• Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors

  2016cites this paper
• microRNA-106a induces the proliferation and apoptosis of glioma cells through regulating JNK/MAPK pathway.

  2016cites this paper
• microRNA-106a induces the proliferation and apoptosis of glioma cells through regulating JNK/MAPK pathway.

  2015cites this paper
• Molekulární genetika u gastrointestinálních stromálních tumorů

  2014cites this paper
• MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis.

  2014cites this paper